Suppr超能文献

相似文献

1
Systematic analysis of CD39, CD103, CD137, and PD-1 as biomarkers for naturally occurring tumor antigen-specific TILs.
Eur J Immunol. 2022 Jan;52(1):96-108. doi: 10.1002/eji.202149329. Epub 2021 Sep 18.
3
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors.
Nat Commun. 2018 Jul 13;9(1):2724. doi: 10.1038/s41467-018-05072-0.
4
Characterization of CD103 CD8 tissue-resident T cells in esophageal squamous cell carcinoma: may be tumor reactive and resurrected by anti-PD-1 blockade.
Cancer Immunol Immunother. 2020 Aug;69(8):1493-1504. doi: 10.1007/s00262-020-02562-3. Epub 2020 Apr 13.
5
Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer.
Clin Cancer Res. 2021 Jul 15;27(14):4089-4100. doi: 10.1158/1078-0432.CCR-20-4394. Epub 2021 May 7.
7
Biomarkers of tumor-reactive CD4 and CD8 TILs associate with improved prognosis in endometrial cancer.
J Immunother Cancer. 2022 Dec;10(12). doi: 10.1136/jitc-2022-005443.
8
CD103CD8 T lymphocytes in non-small cell lung cancer are phenotypically and functionally primed to respond to PD-1 blockade.
Cell Immunol. 2018 Mar;325:48-55. doi: 10.1016/j.cellimm.2018.02.002. Epub 2018 Feb 7.
9
Functional Heterogeneity of CD4 Tumor-Infiltrating Lymphocytes With a Resident Memory Phenotype in NSCLC.
Front Immunol. 2018 Nov 16;9:2654. doi: 10.3389/fimmu.2018.02654. eCollection 2018.

引用本文的文献

1
Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.
Chin Med J (Engl). 2025 Sep 5;138(17):2057-2090. doi: 10.1097/CM9.0000000000003708. Epub 2025 Aug 4.
3
A therapeutic regimen using neoantigen-specific TCR-T cells for HLA-A*2402-positive solid tumors.
EMBO Mol Med. 2025 Feb;17(2):365-383. doi: 10.1038/s44321-024-00184-1. Epub 2025 Jan 2.
5
Clinical-scale, modular manufacturing of tumor-reactive TILs using a closed and automated culture system.
Front Immunol. 2024 Dec 9;15:1483254. doi: 10.3389/fimmu.2024.1483254. eCollection 2024.
6
CD39 Is Expressed on Functional Effector and Tissue-resident Memory CD8+ T Cells.
J Immunol. 2024 Sep 1;213(5):588-599. doi: 10.4049/jimmunol.2400151.
8
CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival.
Gynecol Oncol. 2024 May;184:74-82. doi: 10.1016/j.ygyno.2024.01.029. Epub 2024 Jan 29.
9
Inosine induces stemness features in CAR-T cells and enhances potency.
Cancer Cell. 2024 Feb 12;42(2):266-282.e8. doi: 10.1016/j.ccell.2024.01.002. Epub 2024 Jan 25.

本文引用的文献

1
FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models.
Clin Cancer Res. 2020 Aug 1;26(15):4154-4167. doi: 10.1158/1078-0432.CCR-19-2958. Epub 2020 Apr 28.
3
CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement.
Cancer Immunol Res. 2020 Jun;8(6):781-793. doi: 10.1158/2326-6066.CIR-19-0798. Epub 2020 Apr 9.
4
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition).
Eur J Immunol. 2019 Oct;49(10):1457-1973. doi: 10.1002/eji.201970107.
5
PD-1 regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.
Proc Natl Acad Sci U S A. 2019 May 14;116(20):9999-10008. doi: 10.1073/pnas.1822001116. Epub 2019 Apr 26.
6
Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR.
Cancer Immunol Res. 2019 Apr;7(4):528-533. doi: 10.1158/2326-6066.CIR-18-0888.
8
CD4 T cell help in cancer immunology and immunotherapy.
Nat Rev Immunol. 2018 Oct;18(10):635-647. doi: 10.1038/s41577-018-0044-0.
9
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors.
Nat Commun. 2018 Jul 13;9(1):2724. doi: 10.1038/s41467-018-05072-0.
10
Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells.
Immunity. 2018 May 15;48(5):1029-1045.e5. doi: 10.1016/j.immuni.2018.04.026.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验